IN8bio
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
350 5th Ave Ste 5330, New York, New York...Phone Number
(646) 600-6438Website
www.in8bio.comRevenue
$29.6 MillionStock Symbol
INABIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About IN8bio
IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. The Company is developing allogeneic, autologous and genetically modified gamma-delta T cell therapies. The company was founded in 2016 and is located in New York, New York.Explore more
IN8bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IN8bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
IN8bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at IN8bio
Funding: Get notified immidiatlly once IN8bio has new funding data
Check out if IN8bio is spiking on competitors!
Click to see if IN8bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if IN8bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when IN8bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on IN8bio recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to IN8bio
Compare insights from companies similar to IN8bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IN8bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
IN8bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about IN8bio.
IN8bio financials insights
Gather financial insights about IN8bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
IN8bio Tech Stack
A closer look at the technologies used by IN8bio
Most Recent Scoops
Person-Based
Bioengineering, Medical Research
Person-Based
Engineering, Medical Research
Project
conducted preclinical head-to-head studies comparing INB-619 against two FDA approved drugs Amgen's blinatumomab and Roche's mosunetuzumab demonstrating deeper B cell depletion across all doses tested and significantly lower cytokine levels, including IL-17, IL-16, TNF-alpha, and IL-10, with INB-619.
Medical Research
Project
IN8bio is developing N-trans-caproyltyramine (NCT), a molecule that targets metabolism by activating HNF4-alpha, a master control switch inside cells, to improve mitochondrial biogenesis and fat-burning activity, representing a mechanistically distinct approach from GLP-1 drugs.
Pharmaceuticals
Project
Research & Development, Manufacturing Operations
IN8bio News & Media
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentIN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business HighlightsIN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles PFS in Newly Diagnosed Glioblastoma
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding IN8bio
Sign Up For FreeTo access detailed company insights
IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. The Company is developing allogeneic, autologous and genetically modified gamma-delta T cell therapies. The company was founded in 2016 and is located in New York, New York.... Read More
